CinCor Pharma, Inc.
NASDAQ: CINC0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Marc M. P. de Garidel
- Employees
- 19
- Headquarters
- Boston, United States
- IPO year
- 2022
- Market cap
- $1.3B
- Website
- https://www.cincor.com
Loading CINC…
Loading profile data…Frequently asked questions about CINC
What does CinCor Pharma, Inc. (CINC) do?
CinCor Pharma, Inc. is an emerging biopharmaceutical firm in the clinical development phase, dedicated to pioneering therapeutic solutions for cardiovascular and renal conditions. At the core of its pipeline is CIN-107, an investigational compound currently undergoing Phase II clinical trials for indications such as hypertension, primary aldoste...
Where does CINC trade?
CinCor Pharma, Inc. (CINC) trades on the NASDAQ Global Market.
What sector is CINC in?
CinCor Pharma, Inc. (CINC) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of CinCor Pharma, Inc.?
Marc M. P. de Garidel is the chief executive officer of CinCor Pharma, Inc. (CINC).
Where is CinCor Pharma, Inc. headquartered?
CinCor Pharma, Inc. is headquartered in United States.
Does CINC pay a dividend?
CinCor Pharma, Inc. (CINC) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did CINC go public?
CinCor Pharma, Inc. (CINC) completed its initial public offering in 2022.